NCT06960863

Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma

Transient Elastography (Fibroscan) for Evaluation of Immunotherapy Response in Hepatocellular Carcinoma.

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 80 (estimated)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this prospective cohort study is to evaluate the role of transient elastography (Fibroscan) in predicting the response of immunotherapy in advanced Hepatocellular carcinoma (HCC) patients. Researchers will predict the response to 6 months of HCC immunotherapy regarding improvement of the degree of liver fibrosis, development of liver decompensation, complications, survival, and mortality. Participants will undergo history-taking, clinical examination, laboratory investigations, Child-Pugh classification, Model for End-stage Liver Disease (MELD) score, BCLC staging, abdominal ultrasonography, Triphasic CT abdomen with contrast or MRI (for evaluation of tumor site, size and number), and Fibroscan examination at baseline and follow-up after 6 months.

Conditions

• Hepato Cellular Carcinoma (HCC)

Interventions

Type	Name	Description
RADIATION	fibroscan	Liver fibrosis and steatosis can be staged using Dimensional ultrasound TE (transient elastography).

Timeline

• Start date: 2025-01-26
• Primary completion: 2026-01-15
• Completion: 2026-01-31
• First posted: 2025-05-07
• Last updated: 2025-05-07

Locations

1 site across 1 country: Egypt